{"doi":"10.1136/rmdopen-2022-002534","title":"Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study","abstract":"<jats:sec>\n                  <jats:title>Objective</jats:title>\n                  <jats:p>Antiphospholipid syndrome (APS) is defined by the association of thromboembolic and/or obstetrical clinical manifestations and the presence of antiphospholipid antibodies. The objective of our study was to evaluate the impact of the triple-positive profile in a cohort of 204 APS patients.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>We conducted a retrospective study, including patients with primary or secondary APS, meeting the Sydney criteria with at least one thrombotic and/or obstetrical complication. Clinical characteristics and the risk of relapse (defined by the occurrence of a new thrombotic event and/or a new adverse obstetrical event) between triple-positive and non-triple-positive APS patients were compared.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>204 patients were included in our study, 68 were triple-positive and 136 were single or double positive. 122 patients (59.8%) had primary APS. 67 patients (32.8%) had obstetrical APS, with a higher rate among triple-positive patients (45.6% vs 26.5%, p=0.010), and 170 patients (83.3%) had thrombotic APS, without difference between triple-positive and others. Thrombotic events were more often venous (56.4%) than arterial (37.7%). Triple-positive patients had more placental complications than others (17.6% vs 2.9%, p=0.001) and more non-criteria events (48.5% vs 25.7%, p=0.002). Among non-criteria events, there was a higher frequency of Sneddon syndrome in triple-positive patients (7.4% vs 0.7%, p=0.028). The relapse rate was higher in triple-positive patients than in others (63.2% vs 39,7%, p=0002). In multivariate analysis, the triple-positive profile was associated with a higher risk of relapse (HR 1.63; 95% CI 1.04 to 2.55; p=0.031).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion</jats:title>\n                  <jats:p>The triple-positivity is associated with a higher risk of relapse and obstetrical complications.</jats:p>\n               </jats:sec>","journal":"RMD Open","year":2023,"id":628257,"datarank":0.48283137373023016,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"self_citation_contribution":0.48283137373023016,"citation_network_contribution":0.0,"self_endowment_contribution":0.48283137373023016,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":24,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1575155,"name":"Laure Ricard","orcid":null,"position":1,"is_corresponding":false},{"id":1034858,"name":"Yann Nguyen","orcid":"0000-0002-0866-3824","position":2,"is_corresponding":false},{"id":1626537,"name":"Jean Jacques Boffa","orcid":null,"position":3,"is_corresponding":false},{"id":1626538,"name":"Eric Rondeau","orcid":null,"position":4,"is_corresponding":false},{"id":1626539,"name":"Grigorios Gerotziafas","orcid":null,"position":5,"is_corresponding":false},{"id":1626540,"name":"Ismail Elalamy","orcid":null,"position":6,"is_corresponding":false},{"id":1626541,"name":"Sophie Deriaz","orcid":null,"position":7,"is_corresponding":false},{"id":1626542,"name":"Claire De Moreuil","orcid":null,"position":8,"is_corresponding":false},{"id":1626544,"name":"Virginie Planche","orcid":null,"position":9,"is_corresponding":false},{"id":1626546,"name":"Cathererine Johanet","orcid":null,"position":10,"is_corresponding":false},{"id":1626548,"name":"Francois Millot","orcid":null,"position":11,"is_corresponding":false},{"id":1188004,"name":"Olivier Fain","orcid":null,"position":12,"is_corresponding":false},{"id":1102573,"name":"A. Mékinian","orcid":"0000-0003-2849-3049","position":13,"is_corresponding":false},{"id":1540612,"name":"Charlotte Laurent","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study","abstract":"<jats:sec>\n                  <jats:title>Objective</jats:title>\n                  <jats:p>Antiphospholipid syndrome (APS) is defined by the association of thromboembolic and/or obstetrical clinical manifestations and the presence of antiphospholipid antibodies. The objective of our study was to evaluate the impact of the triple-positive profile in a cohort of 204 APS patients.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>We conducted a retrospective study, including patients with primary or secondary APS, meeting the Sydney criteria with at least one thrombotic and/or obstetrical complication. Clinical characteristics and the risk of relapse (defined by the occurrence of a new thrombotic event and/or a new adverse obstetrical event) between triple-positive and non-triple-positive APS patients were compared.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>204 patients were included in our study, 68 were triple-positive and 136 were single or double positive. 122 patients (59.8%) had primary APS. 67 patients (32.8%) had obstetrical APS, with a higher rate among triple-positive patients (45.6% vs 26.5%, p=0.010), and 170 patients (83.3%) had thrombotic APS, without difference between triple-positive and others. Thrombotic events were more often venous (56.4%) than arterial (37.7%). Triple-positive patients had more placental complications than others (17.6% vs 2.9%, p=0.001) and more non-criteria events (48.5% vs 25.7%, p=0.002). Among non-criteria events, there was a higher frequency of Sneddon syndrome in triple-positive patients (7.4% vs 0.7%, p=0.028). The relapse rate was higher in triple-positive patients than in others (63.2% vs 39,7%, p=0002). In multivariate analysis, the triple-positive profile was associated with a higher risk of relapse (HR 1.63; 95% CI 1.04 to 2.55; p=0.031).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion</jats:title>\n                  <jats:p>The triple-positivity is associated with a higher risk of relapse and obstetrical complications.</jats:p>\n               </jats:sec>","is_dataset_classified":null,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37001919","pmcid":"PMC10069563","openalex_id":"https://openalex.org/W4362472408","authors":[],"funders":[],"total_grants":0,"fwci":4.3407,"citation_percentile":0.95320582,"influential_citations":0,"citation_trend":[{"year":2023,"count":3},{"year":2024,"count":6},{"year":2025,"count":11},{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://rmdopen.bmj.com/content/rmdopen/9/1/e002534.full.pdf","host_type":"journal"},{"url":"https://rmdopen.bmj.com/content/rmdopen/9/1/e002534.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1136/rmdopen-2022-002534","host_type":"publisher"},{"url":"https://doi.org/10.1136/rmdopen-2022-002534","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37001919","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10069563","host_type":"repository"},{"url":"https://doaj.org/article/2c077ad37a2a45bfac2421f3fcabfae4","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10069563/pdf/rmdopen-2022-002534.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10069563","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10069563?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Systemic Lupus Erythematosus Research","Heparin-Induced Thrombocytopenia and Thrombosis","Platelet Disorders and Treatments","Humans","Female","Pregnancy","Antiphospholipid Syndrome","Retrospective Studies","Placenta","Antibodies, Antiphospholipid","Prognosis","Thrombosis"],"mesh_terms":["Female","Humans","Placenta","Pregnancy","Prognosis","Retrospective Studies","Thrombosis","Antiphospholipid Syndrome","Antibodies, Antiphospholipid"],"keywords":["Medicine","Antiphospholipid syndrome","Internal medicine","Retrospective cohort study","Gastroenterology","Cohort","Thrombosis","Autoimmune diseases","Antibodies, anticardiolipin"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T12:27:41.414207Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}